Dana Farber Cancer Institute (DFCI, Harvard Medical School, Cambridge, US) Adopts Genomic Vision's Platform to Develop New Dr...
13 Fevereiro 2020 - 3:30AM
Business Wire
- First FiberVision® S scanner installed in the United States,
at DFCI
- GV complete platform to be used by Prof D’Andrea and Prof
Chowdhury for ambitious research project
- Replication Combing Assay chosen to identify new ovarian and
pancreatic cancer biomarkers
Regulatory News:
GENOMIC VISION (Paris:GV) (FR0011799907 – GV), a
biotechnology company that develops tools and services dedicated to
the analysis and control of changes in the genome, today announced
that its proprietary molecular combing technology is now being
established as routine experimental test at the Dana Farber Cancer
Institute (DFCI). DFCI is one of the world-leading research
organization in the area of cancer research and new therapy
development. From now on, DFCI projects can benefit from the
complete strength of GV technology, by using the new FiberVision® S
scanner, which complements perfectly the GV Suite already in used
for many years.
The two teams of Prof D’Andrea and Prof Chowdhury are going to
use the newly installed GV’s platform, including the FiberVision® S
imaging scanner, to characterize and select new oncology compounds
in ovarian and pancreatic cancer settings. The idea is to discover
among multiple sets of DNA Replication data, generated by GV
Replication Combing Assay (RCA), a biomarker which could predict
drug efficacy. To better discriminate a biomarker and the effect of
a drug, GV technology has been considered the best and more
suitable option for their scientific investigations.
Prof Alan D’Andrea, Director of the Center for DNA Damage and
Repair at the Dana Farber Cancer Institute (DFCI), stated:
“Genomic Vision platform acquisition will enable us to implement
the DNA combing technology at a large scale. We have already shown
that the Replication Combing Assay is an excellent biomarker for
drug efficacy prediction in ovarian cancer. Now we will work on
clinical samples and also in different settings. Today, structural
genomics and NGS is required but not sufficient to understand
complex mechanism involved in cancer progression and especially in
resistance, we have seen it with PARP inhibitors. With Genomic
Vision’s technology we have not only a precious tool for screening
and developing new oncology drugs but also potentially a companion
diagnostic that could help the oncologist to choose the best drug
for the patients”.
The new benchtop size FiberVision® S is considered as the
perfect tool for researchers due to its high flexibility,
resolution and extreme precision. Thanks to this automated imaging
system and the associated detection software FiberStudio®, both the
imaging and analysis time are strongly reduced, allowing
researchers to perform high-throughput projects on replication
dynamics.
Aaron Bensimon, co-founder and CEO of Genomic Vision
commented: “Prof Alan D’Andrea’s vision on personalized
medicine immediately thrilled us when we first met in early 2019.
As he does, we believe that mutations identification is not
sufficient to know if a patient tumor will respond to a treatment.
With our RCA, we can provide the best assay available on the market
to obtain key information on DNA replication parameters. This is
what is needed today to predict efficacy of drugs impacting cell
cycle. We were also glad to provide to Prof D’Andrea and Prof
Chowdhury and their teams the first newest platform in the US
including the scanner FiberVision®S to secure the achievement of
their ambitious project”.
ABOUT GENOMIC VISION
GENOMIC VISION is a biotechnology company developing products
and services dedicated to the analysis (structural and functional)
of genome modifications as well as to the quality and safety
control of these modifications, in particular in genome editing
technologies and biomanufacturing processes. Genomic Vision
proprietary tools, based on DNA combing technology and artificial
intelligence, provide robust quantitative measurements needed to
high confidence characterization of DNA alteration in the genome.
These tools are mainly used for monitoring DNA replication in
cancerous cell, for early cancer detection and the diagnosis of
genetic diseases. Based near Paris, in Bagneux, the Company has
approximately 30 employees.
GENOMIC VISION is a publicly listed company in compartment C of
Euronext’s regulated market in Paris (Euronext: GV – ISIN:
FR0011799907).
For further information, please visit www.genomicvision.com
Member of CAC® Mid & Small, CAC® All-Tradable and
EnterNext© PEA-PME 150 indexes
FORWARD LOOKING STATEMENT
This press release contains implicitly or explicitly certain
forward-looking statements concerning Genomic Vision and its
business. Such forward-looking statements are based on assumptions
that Genomic Vision considers to be reasonable. However, there can
be no assurance that such forward-looking statements will be
verified, which statements are subject to numerous risks, including
the risks set forth in the “Risk Factors” section of the reference
document dated March 28, 2017, available on the web site of Genomic
Vision (www.genomicvision.com) and to the development of economic
conditions, financial markets and the markets in which Genomic
Vision operates. The forward-looking statements contained in this
press release are also subject to risks not yet known to Genomic
Vision or not currently considered material by Genomic Vision. The
occurrence of all or part of such risks could cause actual results,
financial conditions, performance or achievements of Genomic Vision
to be materially different from such forward-looking statements.
This press release and the information contained herein do not
constitute and should not be construed as an offer or an invitation
to sell or subscribe, or the solicitation of any order or
invitation to purchase or subscribe for Genomic Vision shares in
any country. The distribution of this press release in certain
countries may be a breach of applicable laws. The persons in
possession of this press release must inquire about any local
restrictions and comply with these restrictions.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200212005726/en/
Genomic Vision Aaron Bensimon Co-fondateur et Président
du Directoire Tél. : +33 1 49 08 07 50
investisseurs@genomicvision.com Ulysse Communication Bruno
Arabian Tel.:+33142682970 barabian@ulysse-communication.com
NewCap Investor Relations / Strategic Communications Tél. :
+33 1 44 71 94 92 gv@newcap.eu
Genomic Vision (EU:GV)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Genomic Vision (EU:GV)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024